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CASE REPORT

Teriparatide Associated Late Hypercalcemia: A
Report of Two Cases and Literature Review
Jovan Milosavljevic a,*, Asha M. Thomas b
a
b

Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
Division of Endocrinology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA

Abstract
Introduction: Teriparatide, recombinant human parathyroid hormone (1e34), is a safe and usually well-tolerated
medication. We describe two cases of late-onset hypercalcemia associated with teriparatide use and report current evidence of hypercalcemia during the treatment with PTH analogs.
Case report: Case 1 is a 54-year-old man with a history of osteoporosis, previously treated with 6 months of teriparatide,
but had not been consistent in taking the medication. Before restarting teriparatide, his serum calcium, PTH and vitamin
D were normal. Six months into the treatment, he developed asymptomatic hypercalcemia of 11.2 mg/dL 24 h after the
last dose. Repeat serum calcium was normal and treatment was continued. Case 2 is a 75-year old woman with a history
of osteopenia and severe scoliosis. Before starting teriparatide, her calcium, PTH and vitamin D were normal. Six months
into the treatment, she developed asymptomatic hypercalcemia of 12.5 mg/dL. Teriparatide was held and subsequently
her serum calcium normalized.
Discussion: Transient hypercalcemia can occur during treatment with teriparatide and usually resolves within 16 h after
administration. Late hypercalcemia, occurring more than 24 h after the dose, is rarely seen. It is usually mild, asymptomatic and rarely occurs repeatedly. Hypercalcemia occurs more often in patients with pre-existing hypercalcemia or
vitamin D deﬁciency. It is rarely a cause of treatment disruption (0.18e4%).
Conclusion: Clinicians should be aware of this side effect, especially in patients who may be at risk of complications of
hypercalcemia.
Keywords: Teriparatide, Hypercalcemia, Adverse effects

1. Introduction

T

eriparatide, recombinant human parathyroid
hormone (1e34), has a long track record of
safety and it is usually well-tolerated. Side effects of
teriparatide are usually mild and include muscle
pain, weakness, dizziness, headache and nausea.1e3
Hypercalcemia during teriparatide treatment has
been described in the initial clinical trials. It usually
occurs within 4e6 h and resolves by 16e24 h after
dose administration.4 When late hypercalcemia occurs, it is of concern for clinicians. In this paper, we
will report two cases of hypercalcemia during teriparatide therapy. Additionally, we will also review
the available literature regarding hypercalcemia
associated with the use of PTH analogs.

2. Case reports
Case 1 is a 54-year-old man with a history of
osteoporosis, type 1 diabetes, hypothyroidism, hypertension and remote history of calciuria and
nephrolithiasis (more than 5 years ago). Medications
included levothyroxine, simvastatin, bupropion,
venlafaxine, insulin lispro via insulin pump, dulaglutide, ramipril, ﬂuticasone inhaled and aspirin.
Bone mineral density (BMD) using dual energy Xray absorptiometry (DXA) showed lumbar spine Tscore of 2.8, with a corresponding Z score of 2.3,
femoral neck T-score of 1.0, with a corresponding
Z score of 0.2 and total hip T-score of 0.3 with Zscore of 0.1. He had been previously treated with
bisphosphonates for approximately 5 years and had

Abbreviations: PTH, parathyroid hormone; BMD, bone mineral density; DXA, dual energy X-ray absorptiometry.
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Table 1. Case 1 - summary of laboratory data.
Investigation

Prior to treatment

During the treatment

Repeat laboratory data

Reference range

Sodium (mmol/L)
Potassium (mmol/L)
BUN (mg/dL)
Creatinine (mg/dL)
Albumin (g/dL)
Calcium (mg/dL)
25(OH)D (ng/mL)
PTH (pg/mL)
24-h urine calcium (mg)
24-h urine creatinine (g)

138
4.2
11
0.91
4.2
9.3 (8.5e10.1)
49
41.3
238
1.7

145
5.8
12
1.0
NA
11.2 (8.6e10.4)
NA
NA
NA
NA

140
4.5
14
0.86
4.5
10.7 (8.5e10.1)
45.1
NA
NA
NA

135e145
3.5e5.1
7e20
0.5e1.3
3.4e5.0
e
30.0e100.0
8.7e77.1
42e353
0.6e2.5

Abbreviations: BUN ¼ Blood Urea Nitrogen; 25(OH)D ¼ 25-hydroxy-vitamin D; NA ¼ not available.

been on a course of teriparatide for about 6 months,
but had not been consistent in taking the medication. The decision was made to restart teriparatide
20 mg subcutaneously daily for an additional 18
months.
Prior to restarting teriparatide, his initial laboratory data were notable for normal serum calcium of
9.3 mg/dL and normal vitamin D (Table 1). Additionally, due to history of calciuria, 24-h urine calcium studies were obtained and were normal. Six
months into the treatment, he was noted to have
asymptomatic hypercalcemia of 11.2 mg/dL (obtained approximately 24 h after the last injection).
Four days later, a repeat laboratory panel was obtained, showing serum calcium of 10.7 mg/dL with
normal vitamin D. Patient remained on teriparatide
therapy. On subsequent follow-up visits, his serum
calcium remained within normal limits (9.1 mg/dL).
Case 2 is a 75-year-old woman with a history of
osteopenia and severe progressive scoliosis. She
had previously been on a course of raloxifene and
then preventive doses of alendronate. Medications
included 1000 mg calcium and 1000 IU vitamin D
daily, vitamin D 50,000 IU monthly and aspirin
daily. Due to osteopenia, at risk for fracture and
severe debilitating scoliosis, she was started on
20 mg/day of teriparatide. A DXA scan later revealed

lumbar spine T-score of 0.7 with a corresponding
Z score of 1.8, femoral neck T-score of 2.5 with a Zscore of 0.4, total hip T-score of 1.7 with Z-score
of 0.1 and the distal forearm T-score of 2.9 with Zscore of 0.2.
Prior to treatment start, calcium levels were
normal at 9.3 mg/dL with normal PTH and vitamin
D levels (Table 2). Six months into the treatment, the
patient was noted to have asymptomatic hypercalcemia of 12.5 mg/dL (24 h after the last teriparatide
dose). Subsequently, teriparatide treatment was
held. On follow-up visits, serum calcium remained
within normal ranges. Additionally, three months
before the hypercalcemic event, she was noted to
have low 25-hydroxy-vitamin D of 24.2 ng/mL.
However, on a repeat laboratory panel after resolution of hypercalcemia, the vitamin D levels were
normal.

3. Discussion
Given the physiological effects of PTH and hypercalcemia seen in hyperparathyroidism, there was
a natural concern of hypercalcemia with the use of
PTH analogs. Transient increase in serum calcium
can occur within the ﬁrst 4e6 h after 20 mg dose of
teriparatide, with a median increase of 0.4 mg/dL.

Table 2. Case 2 - summary of laboratory data.
Investigation

Prior to treatment

During the treatment

Repeat laboratory data

Reference range

Sodium (mmol/L)
Potassium (mmol/L)
BUN (mg/dL)
Creatinine (mg/dL)
Albumin (g/dL)
Calcium (mg/dL)
25(OH)D (ng/mL)
PTH (pg/mL)
ALP (U/L)
24-h urine calcium (mg)
Calcium/creatinine ratio in 24-h urine (mg/g)

140
4.5
24
0.64
4.3
9.5
33
24
57
210
230

141
4.0
29
0.85
4.3
12.5
NA
NA
143
NA
NA

139
4.1
23
0.65
3.9
9.3
32
83, repeat 43
214
31
57

135e145
3.5e5.1
7e25
0.6e0.93
3.6e5.1
8.6e10.4
30.0e100.0
14e64
33e130
35e250
30e275

Abbreviations: BUN ¼ Blood Urea Nitrogen; 25(OH)D ¼ 25-hydroxy-vitamin D; ALP ¼ alkaline phosphatase; NA ¼ not available.
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However, by 16e24 h after the dose, serum calcium
returns to predose levels, thus hypercalcemia prior
to the morning dose is rarely seen.1,4
The pivotal study in postmenopausal women reported a rate of postdose hypercalcemia at least
once in 11% of women treated with 20 mg/day of
teriparatide, compared to 2% of women in the placebo group.1 Similar postdose hypercalcemia
occurred in men with osteoporosis with an incidence of 6.2%.5 On the other hand, initial clinical
trials did not observe predose hypercalcemia, i.e.,
serum calcium levels above the upper limit of
normal measured more than 16 h after the last dose.
Nonetheless, EUROFORS, a randomized clinical
trial done in 95 centers in Europe, reported 4.3% of
women developing predose hypercalcemia during a
2-year treatment with 20 mg of teriparatide.6
Both of our patients had asymptomatic elevation of
predose calcium. Due to the overall low number of
cases of hypercalcemia in the clinical trials, a more
detailed analysis of factors association with similar
hypercalcemia was limited. However, review of the
literature provides some information. When present,
hypercalcemia is usually mild with 95% of elevated
serum calcium levels remaining less than 11.2 mg/
dL in women treated with a 20 mg/day dose of teriparatide.1 Case 1 patient had asymptomatic elevation of predose calcium of 11.2 mg/dL, however our
second patient had elevation to 12.5 mg/dL. In a
study by Kendler et al. only 0.6% of the study population (total of 4 women) developed similar severe
hypercalcemia with levels greater than 12.5 mg/dL.7
Repeated hypercalcemia rarely occurs.5,8 Orwoll
et al. reported only 2 out of 151 in the 20 mg/day
group and 8 out of 139 men in the 40 mg/day group
experienced hypercalcemia more than once.5
Nevertheless, at month 1 and 3 of treatment, a statistically signiﬁcant increase in serum calcium was
observed (0.2 mg/dL and 0.3 mg/dL respectively).
However, this was thought not to be clinically signiﬁcant. By 12 months of treatment, calcium levels
returned to baseline, pretreatment concentrations.9
Similarly, both of our patients had normalizations of
calcium levels upon retesting.
Hypercalcemia occurred more often in patients with
pre-existing hypercalcemia or vitamin D deﬁciency. In
the study done by Greenspan et al., the rate of predose
hypercalcemia was 28% while on treatment with fulllength recombinant PTH (1e84).10 Although previous
studies on full-length recombinant PTH showed
overall higher incidence of hypercalcemia,9 this study
included women with mild hypercalcemia at baseline
(8.9% of the study population), as well as patients with
vitamin D insufﬁciency. These patients were thought
to have increased endogenous PTH, which could

precipitate hypercalcemia. The current drug label is
recommending avoidance of teriparatide in patients
with hypercalcemia, vitamin D deﬁciency, hyperparathyroidism or unexplained elevation of alkaline
phosphatase (ALP).11 Interestingly, our second patient
was found to have elevated ALP during a follow-up
visit, despite normal pretreatment levels. Nevertheless, treatment was discontinued due to moderate
hypercalcemia.
Our ﬁrst patient did have a remove history of
calciuria and nephrolithiasis (more than 5 years
ago). Although no contraindications exist regarding
the use of teriparatide in patients with history of
kidney stones, the medication has not been studied
in those with urolithiasis.11 Nevertheless, we obtained 24-h urine calcium studies prior to treatment,
which resulted as normal. Despite that, our patient
developed asymptomatic hypercalcemia during the
follow-up.
Similar to our patients, none of the patients in the
clinical trials were reported to have clinical effects of
hypercalcemia.1,5,9 However, several case reports
exist in the literature of severe persistent elevation
of serum calcium (Table 3). Reported cases vary in
their presentation from mild, self-limiting to severe
symptomatic hypercalcemia requiring hospital
admission. Calcium levels in the above case reports
ranged from 10.4 to 17.3 mg/dL. Hajime et al. reported co-occurrence of severe hypophosphatemia
as well.12 Those admitted were treated with intravenous ﬂuids, diuretics and/or intravenous
bisphosphonates.13e16 Sustained hypercalcemia
persisting for a week after teriparatide discontinuation has been reported as well.14 In three patients,
PTH was measured during the hypercalcemic
episode. Levels were suppressed in all cases, which
was thought to be consistent with the physiological
response.12,14,16 In all reported cases, teriparatide
was discontinued (Table 3).
Management of hypercalcemia in the studies with
PTH analogs was done according to an algorithm. If
hypercalcemia persisted on the repeat analysis, researchers would decrease calcium supplementation
to less than 1000 mg daily.17 If persisting hypercalcemia was found, the dose of PTH analog was
reduced by 50%.1,9,18 Hypercalcemia was rarely a
cause of treatment disruption when used as a
treatment of postmenopausal osteoporosis (Neer
et al. 1 out of 541 [0.18%] in 20 mg/day, 9 out of 552
[1.6%] in 40 mg/day; Body et al. 1 out of 73 [1.36%],
40 mg/day).1,18 One study in men with osteoporosis
reported the rate of discontinuation of 2% in 20 mg/
day and 4% in 40 mg/day of teriparatide.5 As yet,
there are no clinical practice recommendations
regarding the treatment discontinuation. In Case 2,
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Table 3. Case reports of teriparatide associated hypercalcemia.
Author (year)

Age, sex Pretreatment Laboratory Data
calcium

Comments

Thiruchelvam (2014)13 65, F

9.3 mg/dL

Calcium 13.8 mg/dL

Hajime (2014)12

49, F

9.3 mg/dL

Karatoprak (2012)14

47, F

9.3 mg/dL

Calcium 10.4 mg/dL
Phosphorus 0.9 mg/dL
iPTH 6 pg/mL
Calcium 14.5 mg/dL
Cr 2.24 mg/dL*
iPTH 4.5 pg/mL

Ayasreh (2012)15

77, M

NA

Sistla (2019)16

74, F

NA

Admitted to the hospital and treated with calcitonin, i.v.
pamidronate and i.v. ﬂuids. TPTD discontinued.
Occurred two weeks after treatment initiation. TPTD was
discontinued and calcium subsequently normalized.

Occurred 7 months after TPTD start. Admitted to hospital
with constipation, nausea, heartburn. Treated with i.v. ﬂuids
and furosemide. TPTD was discontinued and calcium subsequently normalized.
Calcium 12.92 mg/dL
One year after treatment start. Admitted to the hospital and
Phosphorus 2.81 mg/dL treated with i.v. ﬂuids, furosemide. TPTD was discontinued
Cr 2.5 mg/dL**
and calcium subsequently normalized.
iPTH 12.2 pg/mL
25(OH)D 19.8 ng/mL
Calcium 17.3 mg/dL
Admitted to the hospital with confusion and bone pain.
iPTH 3 ng/L
Treated with i.v. ﬂuids, i.v. bisphosphonates and calcitonin.
TPTD was discontinued. Hypercalcemia persisted 3e4
weeks post-discharge.

Abbreviations: TPTD ¼ teriparatide; iPTH ¼ intact PTH; 25(OH)D ¼ 25-hydroxy-vitamin D, Cr ¼ creatinine, i.v ¼ intravenous. Reference
range: calcium 8.5e10.5 mg/dL, iPTH 10e65 pg/mL, 25-hydroxy vitamin D 30e100 ng/mL.
*baseline creatinine 0.78 mg/dL; **baseline creatinine 1.18e1.37 mg/dL.

we did permanently discontinue teriparatide treatment, due to level of hypercalcemia.
It has been suggested that serum calcium should
be assessed before PTH analog use.19 There are
currently no guidelines regarding when to measure
serum calcium. In the clinical trials, usually, serum
calcium was assessed at baseline, 1, 6 and 12 months
after treatment start. It is also important to be aware
of the timing of serum calcium measurement with
teriparatide administration. Measurements post-injection are more likely to reveal transient hypercalcemia. This could potentially lead to more testing,
patients’ concerns and avoidable expense.
Although none of the clinical trials reported
symptomatic hypercalcemia, current drug label instructions include a recommendation to educate
patients on hypercalcemic symptoms and when to
contact a healthcare provider.11

4. Conclusion
Hypercalcemia can occur during treatment with
teriparatide. It is usually mild and asymptomatic.
Although rarely a cause of discontinuation of treatment, it is important to be aware of this side effect in
patients who may be at risk of complications of
hypercalcemia. Further studies are necessary to
identify patients for hypercalcemia.
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